Clinical Trials Directory

Trials / Completed

CompletedNCT02249442

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

An Open-label Study to Determine the Pharmacokinetics of Single-dose and/or Steady-state TPV/r 500/200 mg in Subjects With Mild and Moderate Hepatic Insufficiency

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency

Conditions

Interventions

TypeNameDescription
DRUGTipranavir (TPV)
DRUGRitonavir (r)

Timeline

Start date
2003-10-01
Primary completion
2004-06-01
First posted
2014-09-25
Last updated
2025-01-23

Source: ClinicalTrials.gov record NCT02249442. Inclusion in this directory is not an endorsement.